{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:54Z","timestamp":1766023074221,"version":"3.48.0"},"reference-count":21,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nucl Med Mol Imaging"],"DOI":"10.62347\/lhud5322","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T02:30:01Z","timestamp":1715135401000},"page":"72-77","source":"Crossref","is-referenced-by-count":1,"title":["Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by 68Ga-FAPI PET\/MR scan"],"prefix":"10.62347","volume":"14","author":[{"given":"Mengna","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"RC","year":"2019","unstructured":"Wu RC, Wang P, Lin SF, Zhang M, Song Q, Chu T, Wang BG, Kurman RJ, Vang R, Kinzler K, Tomasetti C, Jiao Y, Shih IM and Wang TL. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. J Pathol 2019; 248: 41-50.","journal-title":"J Pathol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R and Velculescu VE. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 2017; 8: 1093.","journal-title":"Nat Commun"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","unstructured":"Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L and Levine DA. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun 2017; 8: 990.","journal-title":"Nat Commun"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053-1064.","journal-title":"Am J Pathol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13402-020-00513-9","article-title":"Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles","volume":"43","author":"Yousefi","year":"2020","unstructured":"Yousefi M, Dehghani S, Nosrati R, Ghanei M, Salmaninejad A, Rajaie S, Hasanzadeh M and Pasdar A. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. Cell Oncol (Dordr) 2020; 43: 515-538.","journal-title":"Cell Oncol (Dordr)"},{"key":"ref6","unstructured":"Qin C, Song Y, Cai W and Lan X. Dimeric FAPI with potential for tumor theranostics. Am J Nucl Med Mol Imaging 2021; 11: 537-541."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1007\/s00259-022-05847-0","article-title":"Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management","volume":"49","author":"Qin","year":"2022","unstructured":"Qin C, Song Y, Gai Y, Ruan W, Liu Q, Liu F, Zheng D, Zhang P, Liu H, Zhang T, Tao K and Lan X. Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging 2022; 49: 4228-4240.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref8","unstructured":"Masselli G, De Angelis C, Sollaku S, Casciani E and Gualdi G. PET\/CT in pediatric oncology. Am J Nucl Med Mol Imaging 2020; 10: 83-94."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.120.258467","article-title":"(68)Ga-DOTA-FAPI-04 PET\/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET\/CT","volume":"63","author":"Qin","year":"2022","unstructured":"Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, Hu F and Lan X. (68)Ga-DOTA-FAPI-04 PET\/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET\/CT. J Nucl Med 2022; 63: 81-88.","journal-title":"J Nucl Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/ijgc-00009577-200303000-00022","article-title":"An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers: clinical evidence and a research proposal","volume":"13","author":"Belhocine","year":"2003","unstructured":"Belhocine T. An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers: clinical evidence and a research proposal. Int J Gynecol Cancer 2003; 13: 228-233.","journal-title":"Int J Gynecol Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2967\/jnumed.115.158808","article-title":"18F-FDG PET\/CT and PET\/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients","volume":"57","author":"Spick","year":"2016","unstructured":"Spick C, Herrmann K and Czernin J. 18F-FDG PET\/CT and PET\/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients. J Nucl Med 2016; 57: 420-430.","journal-title":"J Nucl Med"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Pean De Ponfilly-Sotier M, Seror R, Nocturne G and Besson FL. (18)F-FDG PET molecular imaging: a relevant tool to investigate chronic inflammatory rheumatisms in clinical practice? Front Med (Lausanne) 2022; 9: 1070445.","DOI":"10.3389\/fmed.2022.1070445"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13244-021-01153-9","article-title":"A review on advances in (18)F-FDG PET\/CT radiomics standardisation and application in lung disease management","volume":"13","author":"Anan","year":"2022","unstructured":"Anan N, Zainon R and Tamal M. A review on advances in (18)F-FDG PET\/CT radiomics standardisation and application in lung disease management. Insights Imaging 2022; 13: 22.","journal-title":"Insights Imaging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.7150\/thno.88335","article-title":"Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis","volume":"13","author":"Ruan","year":"2023","unstructured":"Ruan D, Zhao L, Cai J, Xu W, Sun L, Li J, Zhang J, Chen X and Chen H. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. Theranostics 2023; 13: 4694-4710.","journal-title":"Theranostics"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.2967\/jnumed.123.265751","article-title":"Oncologic staging with (68)Ga-FAPI PET\/CT demonstrates a lower rate of nonspecific lymph node findings than (18)F-FDG PET\/CT","volume":"64","author":"Demmert","year":"2023","unstructured":"Demmert TT, Pomykala KL, Lanzafame H, Pabst KM, Lueckerath K, Siveke J, Umutlu L, Hautzel H, Hamacher R, Herrmann K and Fendler WP. Oncologic staging with (68)Ga-FAPI PET\/CT demonstrates a lower rate of nonspecific lymph node findings than (18)F-FDG PET\/CT. J Nucl Med 2023; 64: 1906-1909.","journal-title":"J Nucl Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1097\/RLU.0000000000004833","article-title":"Head-to-head comparison of 18 F-FDG and 68 Ga-FAPI-04 PET\/CT for radiological evaluation of cervical cancer","volume":"48","author":"Shu","year":"2023","unstructured":"Shu Q, He X, Chen X, Liu M, Chen Y and Cai L. Head-to-head comparison of 18 F-FDG and 68 Ga-FAPI-04 PET\/CT for radiological evaluation of cervical cancer. Clin Nucl Med 2023; 48: 928-932.","journal-title":"Clin Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-023-06512-w","article-title":", Eur J Nucl Med Mol Imaging 2023;50:486-493","volume":"51","author":"Livingstone","year":"2024","unstructured":"Livingstone J, Berovic M and Peters AM. Letter to the editor concerning “Reproducibility of [(18)F]FDG PET\/CT liver SUV as reference or normalisation factor”: Zwezerijnen et al., Eur J Nucl Med Mol Imaging 2023;50:486-493. Eur J Nucl Med Mol Imaging 2024; 51: 342-343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41467-020-16432-0","article-title":"Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids","volume":"11","author":"Lohmussaar","year":"2020","unstructured":"Lohmussaar K, Kopper O, Korving J, Begthel H, Vreuls CPH, van Es JH and Clevers H. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. Nat Commun 2020; 11: 2660.","journal-title":"Nat Commun"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","unstructured":"Zhang S, Dolgalev I, Zhang T, Ran H, Levine DA and Neel BG. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat Commun 2019; 10: 5367.","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Falconer H, Yin L, Gronberg H and Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015; 107: dju410.","DOI":"10.1093\/jnci\/dju410"}],"container-title":["American Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/1\/ajnmmi0154474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:53:07Z","timestamp":1766022787000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajnmmi\/14\/1\/ajnmmi0154474.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/lhud5322","relation":{},"ISSN":["2160-8407"],"issn-type":[{"type":"electronic","value":"2160-8407"}],"subject":[],"published":{"date-parts":[[2024]]}}}